Basic information Safety Supplier Related

(αS,βR)-β-(2,5-Difluorophenyl)-β-hydroxy-α-Methyl-1H-1,2,4-triazole-1-butanenitrile

Basic information Safety Supplier Related

(αS,βR)-β-(2,5-Difluorophenyl)-β-hydroxy-α-Methyl-1H-1,2,4-triazole-1-butanenitrile Basic information

Product Name:
(αS,βR)-β-(2,5-Difluorophenyl)-β-hydroxy-α-Methyl-1H-1,2,4-triazole-1-butanenitrile
Synonyms:
  • Isavuconazole interMediate 7
  • (αS,βR)-β-(2,5-Difluorophenyl)-β-hydroxy-α-Methyl-1H-1,2,4-triazole-1-butanenitrile
  • 241479-74-3 (2S,3R)-3-(2,5-difluorophenyl)-3-hydroxy-2-Methyl-4-(1H-1,2,4-triazol-1-yl)butanenitrile
  • (alphaS,betaR)-beta-(2,5-Difluorophenyl)-beta-hydroxy-alpha-methyl-1H-1,2,4-triazole-1-butanenitrile
  • (2s,3r)-3-(2,5-difluorophenyl)-3-hydroxy-2-methyl-4-(1h-1,2,4-triazol-1-yl)butanenitrile
  • Isavuconazole intermediate
  • (2S,3R)-3-(2,5-Difluorophenyl)-3-hydroxy-2-Methyl-1H-1,2,4-triazole-1-butanenitrile
  • 4-triazole-1-butanenitrile
CAS:
241479-74-3
MF:
C13H12F2N4O
MW:
278.26
EINECS:
1592732-453-0
Mol File:
241479-74-3.mol
More
Less

(αS,βR)-β-(2,5-Difluorophenyl)-β-hydroxy-α-Methyl-1H-1,2,4-triazole-1-butanenitrile Chemical Properties

Melting point:
112-115oC
Boiling point:
522.5±60.0 °C(Predicted)
Density 
1.32±0.1 g/cm3(Predicted)
storage temp. 
Inert atmosphere,Room Temperature
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
10.95±0.29(Predicted)
form 
Solid
color 
Pale Yellow
InChI
InChI=1/C13H12F2N4O/c1-9(5-16)13(20,6-19-8-17-7-18-19)11-4-10(14)2-3-12(11)15/h2-4,7-9,20H,6H2,1H3/t9-,13+/s3
InChIKey
SYSUFNUKZJVPBI-OWKUYNCVNA-N
SMILES
N1(C[C@@](C2=CC(F)=CC=C2F)(O)[C@@H](C)C#N)C=NC=N1 |&1:2,12,r|
More
Less

(αS,βR)-β-(2,5-Difluorophenyl)-β-hydroxy-α-Methyl-1H-1,2,4-triazole-1-butanenitrile Usage And Synthesis

Uses

(αS,βR)-β-(2,5-Difluorophenyl)-β-hydroxy-α-methyl-1H-1,2,4-triazole-1-butanenitrile is an intermediate in the synthesis of Isavuconazole (I777830), an triazole based antifungal agent for the treatment of invasive fungal infections.

Synthesis

1157938-97-0

107-12-0

241479-74-3

(B) In a three-necked reaction flask equipped with a stirrer, propionitrile (4 mol), catalyst (0.1 mol containing 0.05 mol of C-9 cinchona alkaloid-derived primary amine and 0.05 mol of copper complex), benzoic acid (0.1 mol), and N,N-dimethylacetamide (DMA, 0.5 L) were added sequentially. The reaction mixture was cooled to -10 °C with continuous stirring. Subsequently, N,N-dimethylacetamide solution (0.3 L) containing 1-(2,5-difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethanone (1 mol) was slowly added dropwise, keeping the reaction temperature at -10 °C. The progress of the reaction was monitored by thin layer chromatography (TLC) until the reaction was complete. Upon completion of the reaction, the reaction was quenched by the addition of hydrochloric acid solution (1 mol / 0.3 L) and then extracted with ethyl acetate (0.2 L x 3). The organic phases were combined, dried with anhydrous sodium sulfate and concentrated under reduced pressure to give an oil. The oily substance was treated with a solvent mixture of n-heptane/dichloromethane (1:1, v/v), and after recrystallization, filtration and drying, (2S,3R)-3-(2,5-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4-triazol-1-yl)butanenitrile was obtained in off-white solid form in a yield of 80%, with an diastereoisomer ratio (dr) of 97:3.

References

[1] Patent: CN105777740, 2016, A. Location in patent: Paragraph 0019; 0024

(αS,βR)-β-(2,5-Difluorophenyl)-β-hydroxy-α-Methyl-1H-1,2,4-triazole-1-butanenitrileSupplier

Nantong Nuotai Biomedical Technology Co., Ltd. Gold
Tel
0513-82206272 17706270880
Email
2057095228@qq.com
Tianjin Liontec Biopharma Co.,Ltd. Gold
Tel
022-87601716 13920326762
Email
yzhang@liontec.com.cn
Nanjing Vcare PharmaTech Co., Ltd Gold
Tel
025-58741518 13327700685
Email
sales@vcarepharmatech.com
J & K SCIENTIFIC LTD.
Tel
18210857532; 18210857532
Email
jkinfo@jkchemical.com
Chemvon Biotechnology Co., Ltd
Tel
021-50790412
Email
info@chemvon.com